Medicine for Congestive Heart Failure Market Analysis By Drug (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone antagonists, Inotropes, Others), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) & Forecast 2024-2035
- PUBLISHED ON
- 4/11/2023
- NO OF PAGES
- 268
- CATEGORY
- Healthcare & Life Sciences
Congestive heart failure (CHF) is a chronic and progressive condition in which the heart muscle is weakened, resulting in the heart's inability to pump blood efficiently. This can lead to symptoms such as shortness of breath, fatigue, swelling, and difficulty performing daily activities.
The market for medicines to treat CHF is significant, as it is a prevalent condition affecting millions of people worldwide. The market is expected to continue to grow due to the aging population and an increase in the prevalence of risk factors such as hypertension, diabetes, and obesity.
There are several types of medications used to treat CHF, including diuretics, ACE inhibitors, beta-blockers, and aldosterone antagonists. These medications work by reducing fluid buildup in the body, decreasing the workload on the heart, and improving the heart's ability to pump blood.
The market for CHF medications is highly competitive, with several large pharmaceutical companies dominating the market. Some of the key players in the market include Novartis, AstraZeneca, Pfizer, Merck & Co., and Bristol-Myers Squibb.
In recent years, there has been a growing interest in the development of innovative therapies for CHF, such as gene therapy, stem cell therapy, and digital therapeutics. These new therapies have the potential to revolutionize the treatment of CHF and improve outcomes for patients.
Overall, the market for medicines to treat CHF is expected to continue to grow in the coming years, driven by an aging population and an increase in the prevalence of risk factors for the condition. With ongoing research and development, new and innovative therapies may emerge, offering new treatment options for patients with CHF.
Segment Overview
Congestive heart failure (CHF) is a medical condition in which the heart is unable to pump enough blood to meet the body's needs. There are several medicines available for the treatment of CHF, which are broadly classified into the following segments:
1. Angiotensin-converting enzyme (ACE) inhibitors: These medicines block the production of a hormone called angiotensin II, which can cause the blood vessels to narrow and increase blood pressure. Examples of ACE inhibitors include lisinopril, enalapril, and ramipril.
2. Angiotensin receptor blockers (ARBs): These medicines work by blocking the action of angiotensin II on the blood vessels, thereby reducing blood pressure. Examples of ARBs include losartan, candesartan, and valsartan.
3. Beta-blockers: These medicines reduce the heart's workload by slowing down its rate and decreasing the force of its contractions. Examples of beta-blockers include carvedilol, bisoprolol, and metoprolol.
4. Diuretics: These medicines help the body get rid of excess fluid by increasing urine output. Examples of diuretics include furosemide, hydrochlorothiazide, and spironolactone.
5. Digoxin: This medicine increases the strength of the heart's contractions and can help control the heart rate.
6. Inotropic agents: These medicines are used in severe cases of CHF to increase the strength of the heart's contractions. Examples of inotropic agents include dobutamine and milrinone.
7. Aldosterone antagonists: These medicines block the action of a hormone called aldosterone, which can cause the body to retain salt and water, leading to fluid buildup. Examples of aldosterone antagonists include eplerenone and spironolactone.
The choice of medicine(s) for CHF treatment depends on the severity of the condition, the patient's age and overall health, and any other medical conditions they may have. Treatment is typically individualized and may involve a combination of medicines from different segments.
Geographical Overview
The market for medicines used to treat congestive heart failure (CHF) is a global one, with a significant portion of the market located in North America, Europe, and Asia. In these regions, a variety of medications are available to help manage CHF, including:
1. ACE inhibitors - These drugs help relax blood vessels, reducing blood pressure and easing the heart's workload.
2. Beta-blockers - These medications slow the heart rate and reduce blood pressure, helping to relieve stress on the heart.
3. Diuretics - These drugs help the body eliminate excess fluid, reducing swelling and pressure on the heart.
4. Angiotensin receptor blockers (ARBs) - Similar to ACE inhibitors, these medications relax blood vessels and lower blood pressure.
5. Aldosterone antagonists - These medications help block the effects of aldosterone, a hormone that can contribute to fluid buildup in the body.
6. Inotropes - These drugs help strengthen the heart's contractions, improving its ability to pump blood.
The market for CHF medications is expected to continue to grow as the population ages and the incidence of heart failure increases. In addition, new medications and treatment approaches are continually being developed and introduced, further expanding the market.
COVID Impact
The COVID-19 pandemic has affected the medicines for congestive heart failure market in several ways. Here are some of the impacts:
1. Delayed Diagnosis and Treatment: With the focus on COVID-19 patients, many people with heart failure have delayed or avoided seeking medical care, leading to delayed diagnosis and treatment.
2. Supply Chain Disruptions: The pandemic has disrupted global supply chains, leading to shortages of medicines and medical devices used in the treatment of heart failure.
3. Reduced Hospital Admissions: To reduce the risk of infection, hospitals have reduced the number of non-emergency admissions, which has affected the treatment of heart failure patients.
4. Clinical Trials: The pandemic has disrupted ongoing clinical trials, leading to delays in the development of new medicines for heart failure.
5. Economic Impact: The pandemic has had a negative impact on the global economy, leading to reduced healthcare spending and budget cuts for research and development of new medicines.
Despite these challenges, the market for medicines for congestive heart failure is expected to continue to grow in the coming years due to the increasing prevalence of heart failure and the development of new treatments. However, the pandemic has highlighted the need for more resilient supply chains and innovative approaches to the diagnosis and treatment of heart failure.
Competitive Analysis
The congestive heart failure (CHF) medicines market is highly competitive, with a variety of major players competing for market share.
1. Novartis AG
2. Merck & Co., Inc.
3. Pfizer, Inc.
4. AstraZeneca plc
5. GlaxoSmithKline plc
6. Bristol-Myers Squibb Company
7. Boehringer Ingelheim GmbH
8. Sanofi S.A.
9. Mylan N.V.
10. Teva Pharmaceutical Industries Ltd.
These companies offer a range of CHF medications, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, diuretics, and aldosterone antagonists.
Novartis AG is the market leader in the CHF medicines market with its products Entresto and Diovan, which together account for a significant share of the market. Merck & Co., Inc. is another major player in this market, with its product Coreg, a beta-blocker used to treat CHF. Pfizer, Inc. also has a strong presence in the CHF medicines market with its product, Inspra, an aldosterone antagonist.
AstraZeneca plc and GlaxoSmithKline plc are also significant players in this market with their respective products, Atacand and Coreg CR. Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Sanofi S.A., Mylan N.V., and Teva Pharmaceutical Industries Ltd. also have a presence in the CHF medicines market with their respective products.
In summary, the congestive heart failure medicines market is highly competitive, with several major players competing for market share. These companies offer a range of medications used to treat CHF, including ACE inhibitors, ARBs, beta blockers, diuretics, and aldosterone antagonists. The market leader in this space is Novartis AG, with its products Entresto and Diovan.
Historic Year: 2016-2022
Forecast: 2024-2035
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $4250
Only Four Thousand Two Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $5250
Only Five Thousand Two Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $6250
Only Six Thousand Two Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI